The UK's largest event for private investors

Business Design Centre, London, 28 March 2020








Bridge Biotec

Bridge Biotec are developing totally new and safe medicines to treat serious inflammatory diseases such as inflammatory bowel disease, atopic dermatitis and burns. Our safe treatments are small proteins (peptides) that we deliver using a safe nanoparticle delivery technology. They will be safely broken down into their constituent amino acids and will never reach the liver. Bridge are seeking investment show that these peptides switch off inflammation in human inflammatory disease tissue samples and then take the lead compound through to regulatory approval for clinical trials (CTA/IND) over the next 3 years.

Get your ticket

Don't miss out on the UK's largest event for private investors - secure your ticket today.

Book your stand

Join us as exhibitor and get maximum exposure to around 5,000 private investors.  Increase liquidity in your company's shares, generate new leads and build your brand name in the minds of the right audience.

Check out our dedicated 'Investor Access’ microsite for more information or get in touch for a no obligation consultation.

1 + 10 =